2023
DOI: 10.21203/rs.3.rs-2958586/v1
|View full text |Cite
Preprint
|
Sign up to set email alerts
|

Bleomycin alters intratumoral immune response of EBV-associated gastric cancer by ENTPD8 and PCOLCE2

Abstract: Background EBV-associated gastric cancer (EBVaGC) with high PD-L1 level, is most likely to be the next subgroup benefited from immunotherapy. However, complicated with histological and aetiological heterogeneity, tolerance persists which was usually alleviated by clinical adjuvant chemotherapy (bleomycin). Identifying biomarkers of intratumoral immune response was critical for further understanding the direct mechanism of immunotherapy effectiveness. Method Firstly, to identify gene sets involved in both GC … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 75 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?